RayKnowChina Research Map
Shortlist

ChangshaCentral South University (Xiangya)

Third Xiangya Hospital

中南大学湘雅三医院

Listed for 28 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Third Xiangya Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌19 papers led
  2. Hepatocellular carcinoma肝细胞癌41 papers led
  3. Stomach cancer胃癌17 papers led
  4. Lung cancer肺癌36 papers led1 open trial led
  5. Pancreatic cancer胰腺癌22 papers led1 open trial led
  6. Breast cancer乳腺癌36 papers led
  7. Glioma胶质瘤14 papers led
  8. Retinoblastoma视网膜母细胞瘤1 paper led
  9. Chordoma脊索瘤1 paper led
  10. Osteosarcoma骨肉瘤24 papers led
  11. Neuroblastoma神经母细胞瘤2 papers led
  12. Multiple myeloma多发性骨髓瘤19 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  14. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症6 papers led
  15. Lymphoma淋巴瘤12 papers led
  16. Haemophilia A血友病 A0 papers led
  17. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  18. Myasthenia gravis重症肌无力3 papers led
  19. Coronary heart disease冠心病9 papers led
  20. Congenital heart disease先天性心脏病3 papers led
  21. Idiopathic pulmonary fibrosis特发性肺纤维化12 papers led
  22. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  23. Pompe disease庞贝病0 papers led
  24. Behçet disease白塞病1 paper led
  25. Alport syndromeAlport 综合征0 papers led
  26. IgA nephropathyIgA 肾病4 papers led
  27. Osteogenesis imperfecta成骨不全症0 papers led
  28. Leber hereditary optic neuropathyLeber 遗传性视神经病变0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 19 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
19
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 6620232024: 5520242025: 332025

6 hospitals in Changsha for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06788002

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyInduction / concurrent chemotherapyRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led19
  1. Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy.2025Biochimica et biophysica acta. Reviews on cancer
  2. BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.2025International journal of biological sciencesFree full text
  3. Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma.2025International journal of biological sciencesFree full text
  4. PLUNC inhibits invasion and metastasis in nasopharyngeal carcinoma by inhibiting NLRP3 inflammasome activation.2024Biochimica et biophysica acta. Molecular basis of disease
  5. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.2024Cell communication and signaling : CCSFree full text
  6. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  7. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1.2024International immunopharmacology
  8. TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance.2024International journal of biological sciencesFree full text
  9. MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting SOX2.2023Biological chemistry
  10. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.2023Cell biology and toxicology
  11. circRNA_0067717 promotes paclitaxel resistance in nasopharyngeal carcinoma by acting as a scaffold for TRIM41 and p53.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  12. Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma.2023Cellular signalling
  13. The immune escape mechanism of nasopharyngeal carcinoma.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  14. LncRNA SNHG1 promotes nasopharyngeal carcinoma development via targeting miR-424-5p.2023Histology and histopathology
  15. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway.2022Journal of translational medicineFree full text
  16. Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma.2022Pathology, research and practice
  17. Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis.2021BioengineeredFree full text
  18. Transcription factor STAT1 promotes the proliferation, migration and invasion of nasopharyngeal carcinoma cells by upregulating LINC01160.2021Future oncology (London, England)
  19. Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.2021Head & neck
Chinese-language papers (not in the count)2
  1. Analysis and projection of the disease burden of nasopharyngeal carcinoma in China based on the GBD database.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. HDAC6-mediated deacetylation of FLOT2 maintains stability and tumorigenic function of FLOT2 in nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Intestinal Flora Sequencing for Nasopharyngeal CarcinomaCompletedNCT04094545Lead sponsorStart 2018-08
  2. LDRT and Chemoimmunotherapy in NPC With Liver MetastasisRecruitingNCT06788002Study sitePhase 2Start 2025-01
More papers found outside PubMed (not counted)4
  1. Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems2025Open Research (University of Surrey)article
  2. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  3. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023Venue not listedother
  4. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 41 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
41
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 101020232024: 8820242025: 992025

6 hospitals in Changsha for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led41
  1. Detection of macrotrabecular-massive hepatocellular carcinoma based on viscoelastic characteristics obtained by multifrequency magnetic-resonance elastography.2026European radiologyFree full text
  2. MicroRNA-6069 ASO inhibits the growth of hepatocellular carcinoma by PLEKHO1.2025Biochimica et biophysica acta. General subjects
  3. Analysis of influencing factors for achieving textbook outcome after laparoscopic right posterior sectionectomy of hepatocellular carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance.2025International journal of biological macromolecules
  5. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  6. Liver B Cells Promotes MASLD Progression via the Apelin/APLNR System.2025International journal of medical sciencesFree full text
  7. Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  8. Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.2025Journal of experimental & clinical cancer research : CRFree full text
  9. Gene expression profile of anoikis reveals new subtypes of liver cancer and discovery of therapeutic targets and biomarkers.2025Scientific reportsFree full text
  10. Exploration of safety indicators for radiotherapy in hepatocellular carcinoma: A real-world study.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  11. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.2024AgingFree full text
  12. SEH1L siliencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis.2024Apoptosis : an international journal on programmed cell deathFree full text
  13. Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma.2024Biochimica et biophysica acta. Reviews on cancer
  14. ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells.2024Cell communication and signaling : CCSFree full text
  15. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.2024Current medicinal chemistry
  16. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.2024Hepatology international
  17. Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic 2024Journal of gastroenterology and hepatology
  18. Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma.2024Pathology, research and practice
  19. ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.2023BMC medical genomicsFree full text
  20. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.2023Biochemical genetics
  21. PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.2023European journal of medical researchFree full text
  22. A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.2023Frontiers in endocrinologyFree full text
  23. The impact of liver fibrosis on the progression of hepatocellular carcinoma via a hypoxia-immune-integrated prognostic model.2023International immunopharmacology
  24. Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma.2023Journal of nanobiotechnologyFree full text
  25. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJFree full text
  26. CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma.2023Radiology
  27. A novel approach for the analysis of single-cell RNA sequencing identifies TMEM14B as a novel poor prognostic marker in hepatocellular carcinoma.2023Scientific reportsFree full text
  28. Anoikis-related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments.2023The journal of gene medicine
  29. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  30. CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis.2022Immunologic research
  31. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.2022International journal of biological sciencesFree full text
  32. SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis.2022Journal of experimental & clinical cancer research : CRFree full text
  33. Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.2022Liver international : official journal of the International Association for the Study of the Liver
  34. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.2022Oncogene
  35. Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model.2022World journal of surgical oncologyFree full text
  36. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy.2021Journal of drug targeting
  37. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.2021Liver international : official journal of the International Association for the Study of the Liver
  38. Bcl-2 Associated Athanogene 2 (BAG2) is Associated With Progression and Prognosis of Hepatocellular Carcinoma: A Bioinformatics-Based Analysis.2021Pathology oncology research : PORFree full text
  39. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.2021Radiology
  40. Enhanced Chemodynamic Therapy and Chemotherapy via Delivery of a Dual Threat ArtePt and Iodo-Click Reaction Mediated Glutathione Consumption.2021Small methods
  41. Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression.2021Tumori
Chinese-language papers (not in the count)5
  1. SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesRCTFree full text
  3. Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Influence of different region of interest sizes on CT-based radiomics model for microvascular invasion prediction in hepatocellular carcinoma.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesRCTFree full text
  5. [MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status14
  1. Clinical Trial of Radiotherapy in Treating Primary Hepatocellular CarcinomaStatus unknownNCT03614546Lead sponsorN/AStart 2018-10
  2. TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.Status unknownNCT04417764Lead (inferred)Phase 1Start 2019-06
  3. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  4. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Study sitePhase 2Start 2022-04
  5. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12
  6. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  7. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  8. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  9. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  10. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  11. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  12. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01
  13. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03
  14. A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical ResectionTerminatedNCT01402908Study sitePhase 3Start 2011-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 5520232024: 0020242025: 882025

4 hospitals in Changsha for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Posted
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyENT / head & neck surgeryPediatrics
Papers it led17
  1. Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.2025Biochimica et biophysica acta. Reviews on cancer
  2. AKR1B1 Inhibits Ferroptosis and Promotes Gastric Cancer Progression via Interacting With STAT3 to Activate SLC7A11.2025Cell biology international
  3. Circular RNA TFRC/SCD1 mRNA interaction regulates ferroptosis and metastasis in gastric cancer.2025Cell death & diseaseFree full text
  4. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.2025Clinical nuclear medicine
  5. Metabolic reprogramming in Helicobacter pylori infection: from mechanisms to therapeutics.2025Frontiers in cellular and infection microbiologyFree full text
  6. TRAF1 promotes the progression of Helicobacter pylori-associated gastric cancer through EGFR/STAT/OAS signalling.2025Life sciences
  7. VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis.2025Microbiological research
  8. The expression signature, prognostic significance and immune cell infiltration of the OAS gene family in gastric cancer.2025Scientific reportsFree full text
  9. Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer.2023BMC medical genomicsFree full text
  10. LHPP promotes the intracellular reactive oxygen species accumulation and sensitivity of gastric cancer to cisplatin via JNK and p38 MAPK pathways.2023Histology and histopathology
  11. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJFree full text
  12. Comprehensive analysis of COMMD10 as a novel prognostic biomarker for gastric cancer.2023PeerJFree full text
  13. Clinicopathological and prognostic significance of LKB1 expression in gastric cancer: a systematic review and meta-analysis.2023Scientific reportsFree full text
  14. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.2022BMJ openFree full text
  15. A deep learning method to assist with chronic atrophic gastritis diagnosis using white light images.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019.2022Scientific reportsFree full text
  17. The impact of robotic technology on the learning curve for robot-assisted gastrectomy in the initial clinical application stage.2022Surgical endoscopy
Chinese-language papers (not in the count)3
  1. Clinical characteristics of non-HPV infection-associated gastric-type endocervical adenocarcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Comparison of the learning curve of robot-assisted and laparoscopic-assisted gastrectomy.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Risk factors for complications of therapeutic endoscopy for upper gastrointestinal subepithelial lesions.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Domestic Surgical Robot Clinical StudyStatus unknownNCT02752698Lead sponsorN/AStart 2015-01
  2. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  3. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 36 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
36
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 9920232024: 5520242025: 882025

6 hospitals in Changsha for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07138755

    Age 18 years to 75 years (registered criteria)

    Led by Third Xiangya Hospital; 1 listed hospital as study siteChangsha

  2. Recruiting
    ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT06951646

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang

  3. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  4. Recruiting
    Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07886047

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha

  5. Recruiting
    Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07886229

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha

  6. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  7. Recruiting
    Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06840704

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

  8. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  9. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  10. Recruiting
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07217301

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou

  11. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  12. Not yet recruiting
    Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07882628

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha

  13. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyPathology / laboratory medicineNeurosurgery

Over half of these papers are lab or animal studies.

Papers it led36
  1. Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study.2026Lung cancer (Amsterdam, Netherlands)
  2. Bilirubin nanoparticles modulate Treg/Th17 cells and functional metabolism of gut microbiota to inhibit lung adenocarcinoma.2025Biochimica et biophysica acta. Molecular basis of disease
  3. Daurisoline inhibits glycolysis of lung cancer by targeting the AKT-HK2 axis.2025Cancer biology & therapyFree full text
  4. Targeting MGST1 Makes Non-Small Cell Lung Cancer Cells Sensitive to Radiotherapy by Epigenetically Enhancing ALOX15-Mediated Ferroptosis.2025Current cancer drug targets
  5. Spatial features of tumor-infiltrating lymphocytes in primary lesions of lung adenocarcinoma predict lymph node metastasis.2025Journal of translational medicineFree full text
  6. Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.2025Nature communicationsFree full text
  7. Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy.2025Radiation oncology (London, England)Free full text
  8. Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study.2025Scientific reportsFree full text
  9. Targeting EGFR-Mcl-1 Axis by Piperlongumine as a Novel Strategy for Non-Small Cell Lung Cancer Therapy.2025The American journal of Chinese medicine
  10. Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.2024BMC cancerFree full text
  11. Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.2024BMC pulmonary medicineFree full text
  12. Overexpression of transcription factor TBX5 inhibits the activation of YAP1-TEAD1 pathway to promote ferroptosis in lung cancer cells.2024Biochemical and biophysical research communications
  13. Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.2024International journal of cancerFree full text
  14. S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.2024Journal of experimental & clinical cancer research : CRFree full text
  15. BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.2023Cancer scienceFree full text
  16. Survivin degradation by bergenin overcomes pemetrexed resistance.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  17. Gastrodin destabilizes survivin and overcomes pemetrexed resistance.2023Cellular signalling
  18. Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway.2023Journal of biochemical and molecular toxicology
  19. Crosstalk between the lung microbiome and lung cancer.2023Microbial pathogenesis
  20. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJFree full text
  21. Construction and validation of a novel prognostic model of neutrophil‑related genes signature of lung adenocarcinoma.2023Scientific reportsFree full text
  22. Comprehensive analysis of cuproptosis and copper homeostasis genotyping and related immune land scape in lung adenocarcinoma.2023Scientific reportsFree full text
  23. Betulinaldehyde exhibits effective anti-tumor effects in A549 cells by regulating intracellular autophagy.2023Scientific reportsFree full text
  24. Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.2022BioMed research internationalFree full text
  25. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.2022Cancer scienceFree full text
  26. Preoperative Body Composition Combined with Tumor Metabolism Analysis by PET/CT Is Associated with Disease-Free Survival in Patients with NSCLC.2022Contrast media & molecular imagingFree full text
  27. Combined Microbiome and Metabolome Analysis Reveals a Novel Interplay Between Intestinal Flora and Serum Metabolites in Lung Cancer.2022Frontiers in cellular and infection microbiologyFree full text
  28. Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma.2022Scientific reportsFree full text
  29. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.2022Scientific reportsFree full text
  30. Xanthohumol inhibits non-small cell lung cancer by activating PUMA-mediated apoptosis.2022Toxicology
  31. MiR-3130-5p is an intermediate modulator of 2q33 and influences the invasiveness of lung adenocarcinoma by targeting NDUFS1.2021Cancer medicineFree full text
  32. Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells.2021Journal of cellular and molecular medicineFree full text
  33. Association between Sleep Traits and Lung Cancer: A Mendelian Randomization Study.2021Journal of immunology researchFree full text
  34. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.2021Oncogene
  35. The effects of the miR-21/SMAD7/TGF-β pathway on Th17 cell differentiation in COPD.2021Scientific reportsFree full text
  36. Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)2
  1. Application of immune checkpoint inhibitors in colorectal cancer.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. [Clinical study of circulating tumor cells in monitoring the efficacy of neoadjuvant immunotherapy for non-small cell lung cancer].2021Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status23
  1. The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer PatientsRecruitingNCT07138755Lead sponsorPhase 2Start 2025-08
  2. A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionRecruitingNCT07367529Study sitePhase 1/Phase 2Start 2026-02
  3. ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)RecruitingNCT06951646Study sitePhase 2Start 2026-03
  4. Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung CancerRecruitingNCT07886047Study sitePhase 1Start 2026-05
  5. Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung CancerNot yet recruitingNCT07882628Study siteStart 2026-10
  6. Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CancerRecruitingNCT07886229Study sitePhase 1Start 2026-06
  7. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Study sitePhase 3Start 2025-12
  8. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  9. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingNCT06712316Study sitePhase 2/Phase 3Start 2025-01
  10. A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerRecruitingNCT07217301Study sitePhase 3Start 2025-11
  11. Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung CancerRecruitingNCT06840704Study sitePhase 3Start 2025-02
  12. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  13. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  14. A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsActive, not recruitingNCT07160335Study sitePhase 1Start 2025-09
  15. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerActive, not recruitingNCT06984588Study sitePhase 2/Phase 3Start 2024-03
  16. Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian CancerCompletedNCT05815862Study sitePhase 2Start 2023-02
  17. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Status unknownNCT05922345Study sitePhase 3Start 2023-06
  18. A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05047250Study sitePhase 3Start 2022-06
  19. A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Study sitePhase 3Start 2020-05
  20. A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCStatus unknownNCT04033354Study sitePhase 3Start 2019-08
  21. Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT04044170Study sitePhase 2Start 2019-07
  22. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Study sitePhase 3Start 2018-11
  23. Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCStatus unknownNCT03300115Study sitePhase 2Start 2017-05

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 22 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
22
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 4420232024: 4420242025: 332025

5 hospitals in Changsha for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07231094

    Age 18 years to Not stated (registered criteria)

    Led by Third Xiangya HospitalChangsha

  2. Recruiting
    Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07529626

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 2 listed hospitals as study sitesChangsha, Shanghai, Xi'an

  3. Not yet recruiting
    A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07906691

    Age 18 years to 45 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicineMedical oncology
Papers it led22
  1. MMP28 promotes tumorigenesis and gemcitabine resistance in pancreatic cancer by promoting glycolysis through interaction with SND1.2026Biochemical pharmacology
  2. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.2025Clinical nuclear medicine
  3. The miR-1305/KLF5 negative regulatory loop affects pancreatic cancer cell proliferation and apoptosis.2025Human cell
  4. Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021.2025Scientific reportsFree full text
  5. Targeting SMYD2 promotes ferroptosis and impacts the progression of pancreatic cancer through the c-Myc/NCOA4 axis-mediated ferritinophagy.2024Biochimica et biophysica acta. General subjects
  6. Clinical value of endoscopic ultrasound sound speed in differential diagnosis of pancreatic solid lesion and prognosis of pancreatic cancer.2024Cancer medicineFree full text
  7. 24-Hour Urinary Sodium Excretion Is Associated With Increased Risk of Pancreatic Cancer: A Prospective Cohort Study.2024Clinical and translational gastroenterologyFree full text
  8. A retrospective comparative study on the treatment of non-metastatic pancreatic cancer using high-intensity focused ultrasound versus radical surgery.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  9. Contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) MASTER: A novel deep learning-based system in pancreatic mass diagnosis.2023Cancer medicineRCTFree full text
  10. The efficacy and safety of endoscopic ultrasound-guided fine-needle biopsy in gallbladder masses.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  11. Endoscopic ultrasound diagnosis system based on deep learning in images capture and segmentation training of solid pancreatic masses.2023Medical physics
  12. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer.2023Science translational medicine
  13. DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.2022Acta biochimica et biophysica SinicaFree full text
  14. The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling.2022Cancer biology & therapyFree full text
  15. Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer.2022Frontiers in immunologyFree full text
  16. Primary pancreatic lymphoma diagnosed by endoscopic ultrasound-guided fine needle biopsy.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  17. Assessment of causal effects of visceral adipose tissue on risk of cancers: a Mendelian randomization study.2022International journal of epidemiologyFree full text
  18. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.2021Frontiers in immunologyFree full text
  19. Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer.2021International journal of medical sciencesFree full text
  20. Comparison between modified wet suction and dry suction technique for endoscopic ultrasound-guided fine-needle biopsy in pancreatic solid lesions.2021Journal of gastroenterology and hepatologyRCT
  21. Over-expressed RHEB promotes the progression of pancreatic adenocarcinoma.2021Life sciences
  22. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.2021Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Chinese-language papers (not in the count)1
  1. Diagnostic yield and safety of pancreatic cystic lesions: A comparison between EUS-FNA and EUS-FNB.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status6
  1. A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic CancerNot yet recruitingNCT07231094Lead sponsorEarly phase 1Start 2025-11
  2. Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.Status unknownNCT06655233Lead sponsorStart 2024-10
  3. A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDACStatus unknownNCT04794140Lead sponsorN/AStart 2021-01
  4. A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy ParticipantsNot yet recruitingNCT07906691Study sitePhase 1Start 2026-11
  5. Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic CancerRecruitingNCT07529626Study siteStart 2026-05
  6. 25G and 22G Puncture NeedlesStatus unknownNCT05101772Study siteStart 2021-09

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 36 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
36
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 101020222023: 8820232024: 9920242025: 772025

4 hospitals in Changsha for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07697443

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan

  2. Not yet recruiting
    Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
    Phase
    Phase 4
    Started
    2023-10
    Posted
    Registry
    NCT05860907

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led36
  1. PAK2 promotes CTC cluster formation by phosphorylating E-cadherin to enhance cell-cell adhesion in breast cancer.2025Breast cancer research : BCRFree full text
  2. Microplastics accumulated in breast cancer patients lead to mitophagy via ANXA2-mediated endocytosis and IL-17 signaling pathway.2025Environmental pollution (Barking, Essex : 1987)
  3. Potential role of CFLAR in enhancing 5-FU sensitivity and modulating immune cell infiltration in breast cancer.2025European journal of medical researchFree full text
  4. A prognostic model for basal-like breast cancer based on beta-alanine metabolism genes: EHHADH as a potential biomarker and target for drug screening.2025Genes & genomics
  5. Probiotics prevent pegylated liposomal doxorubicin-associated hand-foot syndrome and oral mucositis of breast cancer patients following surgery and chemotherapy: a randomized placebo-controlled trial.2025International journal of surgery (London, England)RCT
  6. Glycosylated protein-related microenvironmental features in breast cancer are associated with patient prognosis.2025Mammalian genome : official journal of the International Mammalian Genome Society
  7. The effects of emotional distress on the postoperative survival and progression in patients with breast cancer: a prospective observational study.2025World journal of surgical oncologyFree full text
  8. The Usage of Mesh and Relevant Prognosis in Implant Breast Reconstruction Surgery: A Meta-analysis.2024Aesthetic plastic surgery
  9. Effects of dietary habits and catheterization type on breast cancer-related lymphedema: a retrospective cohort study.2024BMC cancerFree full text
  10. A comprehensive approach for evaluating lymphovascular invasion in invasive breast cancer: Leveraging multimodal MRI findings, radiomics, and deep learning analysis of intra- and peritumoral regions.2024Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  11. Endocrine cancer trends 1990-2021: global disparities and health inequalities.2024Endocrine-related cancer
  12. POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis.2024Epigenomics
  13. Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.2024International journal of cancerFree full text
  14. Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.2024International journal of cancer
  15. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.2024Journal of nanobiotechnologyFree full text
  16. Platelet Membrane-Camouflaged Silver Metal-Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer.2024Molecular pharmaceutics
  17. Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer.2023BMC cancerFree full text
  18. Global research trends and prospects related to tumor microenvironment within Triple Negative Breast Cancer: a bibliometric analysis.2023Frontiers in immunologyFree full text
  19. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.2023International journal of nanomedicineFree full text
  20. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1.2023Journal of translational medicineFree full text
  21. Erythrocyte membrane-camouflaged DNA-functionalized upconversion nanoparticles for tumor-targeted chemotherapy and immunotherapy.2023Nanoscale
  22. CPNE1 mediates glycolysis and metastasis of breast cancer through activation of PI3K/AKT/HIF-1α signaling.2023Pathology, research and practice
  23. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJFree full text
  24. Copper homeostasis-associated gene PRNP regulates ferroptosis and immune infiltration in breast cancer.2023PloS oneFree full text
  25. Optimism and symptoms of anxiety and depression among Chinese women with breast cancer: the serial mediating effect of perceived social support and benefit finding.2022BMC psychiatryFree full text
  26. miR-1290 modulates the radioresistance of triple-negative breast cancer by targeting NLRP3-mediated pyroptosis.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  27. Breast cancer combined with contralateral neck lymph node metastasis: a case report.2022Diagnostic pathologyFree full text
  28. Study of tRNA-Derived Fragment tRF-20-S998LO9D in Pan-Cancer.2022Disease markersFree full text
  29. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.2022Drug metabolism and disposition: the biological fate of chemicalsFree full text
  30. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial.2022European journal of cancer (Oxford, England : 1990)RCT
  31. Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model.2022Frontiers in endocrinologyFree full text
  32. Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis.2022Investigational new drugs
  33. Safety of Breast Cancer Mastoscopic Surgery from the Perspective of Immunity and Adipokines.2022Journal of investigative surgery : the official journal of the Academy of Surgical ResearchRCT
  34. Hormone Receptor Expression on Endocrine Therapy in Patients with Breast Cancer: A Meta-Analysis.2022The American surgeon
  35. Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance.2021Clinical epigeneticsFree full text
  36. Tumor microenvironment-responsive multifunctional nanoplatform based on MnFe2O4-PEG for enhanced magnetic resonance imaging-guided hypoxic cancer radiotherapy.2021Journal of materials chemistry. B
Chinese-language papers (not in the count)1
  1. [Application progress of single-cell RNA sequencing technology in breast development and related diseases].2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer SubjectsRecruitingNCT07697443Study sitePhase 1/Phase 2Start 2026-09
  2. Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisNot yet recruitingNCT05860907Study sitePhase 4Start 2023-10
  3. PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast CancerCompletedNCT05052437Study sitePhase 1Start 2020-10
  4. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Study sitePhase 3Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 14 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 3320232024: 2220242025: 332025

4 hospitals in Changsha for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryNeurologyPathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led14
  1. Correlation between serum GFAP and 3-NT levels and the degree of neuronal injury in patients with glioma after surgery, and its diagnostic value.2025Biomarkers in medicineFree full text
  2. PLIN1 suppresses glioma progression through regulating lipid metabolism.2025Cell death & diseaseFree full text
  3. HOXD8 drives Glioma progression through epithelial-mesenchymal transition regulation: Implications for prognosis and targeted therapy.2025Experimental cell research
  4. CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.2024Journal of neuro-oncology
  5. PSMA2 promotes glioma proliferation and migration via EMT.2024Pathology, research and practice
  6. Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.2023Frontiers in immunologyFree full text
  7. circPKD2 inhibits the glioma cell proliferation, invasion and glycolytic metabolism through regulating the miR-1278/LATS2 axis.2023Neuroscience letters
  8. High expression of six-transmembrane epithelial antigen of prostate 3 promotes the migration and invasion and predicts unfavorable prognosis in glioma.2023PeerJFree full text
  9. CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.2022Cell death & diseaseFree full text
  10. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.2022Frontiers in immunologyFree full text
  11. Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.2022Neurochemistry international
  12. Early and Bi-hemispheric seizure onset in a rat glioblastoma Multiforme model.2022Neuroscience lettersFree full text
  13. Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.2021CNS neuroscience & therapeuticsFree full text
  14. Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.2021CNS neuroscience & therapeuticsFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Changsha for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Changsha for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 24 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
24
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 3320232024: 111120242025: 552025

10 hospitals in Changsha for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led24
  1. Development of a prognostic model for osteosarcoma based on macrophage polarization-related genes using machine learning: implications for personalized therapy.2025Clinical and experimental medicineFree full text
  2. Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma.2025Communications biologyFree full text
  3. m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis.2025International immunopharmacology
  4. Biopolymer-based bone scaffold for controlled Pt (IV) prodrug release and synergistic photothermal-chemotherapy and immunotherapy in osteosarcoma.2025Journal of nanobiotechnologyFree full text
  5. Decoding the role of SLC25A5 in osteosarcoma drug resistance and CD8+ T cell exhaustion: The therapeutic potential of phyllanthin.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Single-Atom Cu Nanozyme-Loaded Bone Scaffolds for Ferroptosis-Synergized Mild Photothermal Therapy in Osteosarcoma Treatment.2024Advanced healthcare materials
  7. The Targeted Therapies for Osteosarcoma via Six Major Pathways.2024Current molecular pharmacology
  8. RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.2024Environmental toxicology
  9. Identification of an ADME-related gene for forecasting the prognosis and responding to immunotherapy in sarcomas.2024European journal of medical researchFree full text
  10. Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.2024Frontiers in immunologyFree full text
  11. METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m6 A-dependent manner.2024Journal of cellular physiology
  12. M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting ACSF2 deubiquitination.2024Molecular carcinogenesis
  13. Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models.2024Molecular carcinogenesis
  14. Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma.2024The journal of gene medicine
  15. Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.2024The journal of gene medicine
  16. Antigen processing and presentation-related signature-derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation.2024The journal of gene medicine
  17. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.2023Frontiers in immunology
  18. Prognosis-related VDAC1 regulates the proliferation and apoptosis of osteosarcoma cells via the MAPK signaling pathway.2023Genomics
  19. Exosomal miR-181a-5p derived from SAOS-2 cells promotes macrophages M2 polarization by targeting RORA.2023The Kaohsiung journal of medical sciencesFree full text
  20. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma.2022Journal of translational medicineFree full text
  21. A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.2021ACS applied materials & interfaces
  22. Effect of the Notch1-mediated PI3K-Akt-mTOR pathway in human osteosarcoma.2021AgingFree full text
  23. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.2021Frontiers in immunologyFree full text
  24. LncRNA-ROR/microRNA-185-3p/YAP1 axis exerts function in biological characteristics of osteosarcoma cells.2021Genomics
Chinese-language papers (not in the count)1
  1. Prognositic value of anoikis and tumor immune microenvironment-related gene in the treatment of osteosarcoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
Earlier papers (2016–2020)14
  1. WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m6A-dependent manner.2020Cell death & disease
  2. miR-485-5p/HSP90 axis blocks Akt1 phosphorylation to suppress osteosarcoma cell proliferation and migration via PI3K/AKT pathway.2020Journal of physiology and biochemistry
  3. LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis.2020Molecular medicine (Cambridge, Mass.)
  4. High SENP3 Expression Promotes Cell Migration, Invasion, and Proliferation by Modulating DNA Methylation of E-Cadherin in Osteosarcoma.2020Technology in cancer research & treatment
  5. Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway.2019Journal of cellular and molecular medicine
  6. Interleukin-1β/nuclear factor-κB signaling promotes osteosarcoma cell growth through the microRNA-181b/phosphatase and tensin homolog axis.2019Journal of cellular biochemistry
  7. miR-194 Suppresses Proliferation and Migration and Promotes Apoptosis of Osteosarcoma Cells by Targeting CDH2.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  8. miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway.2017Biochemical and biophysical research communications
  9. IL-1β-induced NF-κB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  10. Primary osteosarcoma of frontal bone: A case report and review of literature.2017Medicine
  11. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.2017Oncotarget
  12. The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  13. [MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  14. [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

7 hospitals in Changsha for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 7720232024: 4420242025: 552025

4 hospitals in Changsha for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsRelapse & resistanceCAR-T & cell therapy
Papers it led19
  1. Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.2025Cancer immunology, immunotherapy : CIIFree full text
  3. MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy.2025Cell communication and signaling : CCSFree full text
  4. Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes.2025Hematology (Amsterdam, Netherlands)
  5. Exosomal tRF-1003 induces angiogenesis via regulating the HIF1α/VEGF signaling in multiple myeloma.2025International immunopharmacology
  6. Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity.2024Biochimica et biophysica acta. Molecular basis of disease
  7. Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.2024Current treatment options in oncology
  8. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.2024International immunopharmacology
  9. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.2024Journal of translational medicineFree full text
  10. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.2023Chemico-biological interactions
  11. Exosomal miR-21-5p derived from multiple myeloma cells promote renal epithelial-mesenchymal transition through targeting TGF-β/SMAD7 signalling pathway.2023Clinical and experimental pharmacology & physiology
  12. Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  13. CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.2023International journal of pharmaceutics
  14. Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?2023Journal of clinical nursing
  15. IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma.2023Scientific reportsFree full text
  16. The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  17. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.2021Annals of hematologyFree full text
  18. tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma.2021BMC bioinformaticsFree full text
  19. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.2021International journal of medical sciencesFree full text
Chinese-language papers (not in the count)4
  1. Clinical significance of CD45 and CD200 expression in newly diagnosed multiple myeloma patients.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Construction of a treatment response prediction model for multiple myeloma based on multi-omics and machine learning.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Diagnosis and treatment of multiple myeloma in Hunan Province.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Research progress in proteasome inhibitor resistance to multiple myeloma.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  3. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  4. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  5. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  6. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  7. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Study sitePhase 1Start 2019-12
  8. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  9. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

4 hospitals in Changsha for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildrenAntibody & targeted drugs

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 6 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 0020242025: 222025

4 hospitals in Changsha for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensEBV & infection triggersChildren
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 12 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 0020232024: 1120242025: 332025

5 hospitals in Changsha for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Pediatric T-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06855810

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan

  2. Recruiting
    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05768529

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology

Over half of these papers are lab or animal studies.

Papers it led12
  1. Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.2025Blood
  2. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.2025Cancer immunology, immunotherapy : CIIFree full text
  3. Challenges in Diagnosing Non-Nasal Natural Killer/T-Cell Lymphoma Mimicking Behçet Disease: A Case Report.2025The American journal of case reportsFree full text
  4. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.2024Molecular cancerFree full text
  5. CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.2022Cytotherapy
  6. Primary pancreatic lymphoma diagnosed by endoscopic ultrasound-guided fine needle biopsy.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  7. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.2022Human gene therapy
  8. Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.2021Cancer medicineFree full text
  9. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.2021Cancer scienceFree full text
  10. Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma.2021Journal of nanobiotechnologyFree full text
  11. Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma.2021Journal of nanobiotechnologyFree full text
  12. Construction of biomimetic silver nanoparticles in the treatment of lymphoma.2021Materials science & engineering. C, Materials for biological applications
All its trials on ClinicalTrials.gov, any status8
  1. Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Study sitePhase 2/Phase 3Start 2025-03
  2. Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05768529Study sitePhase 1/Phase 2Start 2023-03
  3. A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell LymphomaActive, not recruitingNCT05954910Study siteStart 2023-08
  4. AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)CompletedNCT06511869Study sitePhase 2Start 2022-03
  5. ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLStatus unknownNCT04578613Study sitePhase 3Start 2021-01
  6. Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Study sitePhase 1/Phase 2Start 2020-04
  7. A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Study sitePhase 1Start 2016-12
  8. Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)CompletedNCT01938001Study sitePhase 3Start 2013-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Changsha for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Changsha for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

4 hospitals in Changsha for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStandard immunotherapyBiologic & complement drugsAntibodies & diagnosis
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 9 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
9
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 1120232024: 3320242025: 112025

4 hospitals in Changsha for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePediatricsNephrology
Papers it led9
  1. Association of psoriasis and genetic predisposition for the risk of cardiometabolic diseases: a population-based cohort study.2025Clinical and experimental dermatology
  2. EP300 improves endothelial injury and mitochondrial dysfunction in coronary artery disease by regulating histone acetylation of SOCS1 promoter via inhibiting JAK/STAT pathway.2024Cytokine
  3. Genetic relationship between ageing and coronary heart disease: a Mendelian randomization study.2024European geriatric medicine
  4. Impact of white blood cell count on the development of contrast-induced acute kidney injury in patients receiving percutaneous coronary intervention.2024PeerJFree full text
  5. One-stop combined CT angiography of coronary and craniocervical arteries: recommended as the first examination for patients suspected of coronary or craniocervical artery disease.2023European radiology
  6. Multimorbidity and combined interventions for patients with coronary heart disease in Chinese population: Latent class analysis of a multi-center study.2022International journal of cardiology
  7. Identification of differentially expressed genes and the role of PDK4 in CD14+ monocytes of coronary artery disease.2021Bioscience reportsFree full text
  8. Single-nucleotide Polymorphism rs17860041 A/C in the Promoter of the PPIA Gene is Associated with Susceptibility to Kawasaki Disease in Chinese Children.2021Immunological investigations
  9. 1H NMR-based metabolomics study of the dynamic effect of Xue-Fu-Zhu-Yu capsules on coronary heart disease rats induced by high-fat diet, coronary artery ligation.2021Journal of pharmaceutical and biomedical analysis
Chinese-language papers (not in the count)2
  1. Evaluation of myocardial perfusion and systolic function in patients with coronary heart disease by myocardial contrast echocardiography and 2-dimensional speckle tracking imaging.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Effect of lipoprotein α on coronary stents expansion and its risk factors.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Study on the Registration of Coronary Heart Disease Patients Undergoing PCICompletedNCT02888652Lead sponsorStart 2015-09
  2. Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)CompletedNCT04624854Study sitePhase 4Start 2020-10
  3. Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumCompletedNCT03671603Study siteStart 2018-11
  4. The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for VicagrelCompletedNCT03599284Study sitePhase 2Start 2018-08
  5. Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)Status unknownNCT02448524Study sitePhase 3Start 2015-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Changsha for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 12 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.2%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 2220242025: 222025

6 hospitals in Changsha for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led12
  1. A Rare TERT Mutation Associated with Idiopathic Pulmonary Fibrosis and COPD in a Chinese Family.2025Balkan medical journalFree full text
  2. Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages.2025International immunopharmacology
  3. Identification of key mitochondria-related genes and their potential crosstalk role with immune pattern in Idiopathic pulmonary fibrosis.2024Gene
  4. Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.2024Scientific reportsFree full text
  5. Identification of the shared genes and immune signatures between systemic lupus erythematosus and idiopathic pulmonary fibrosis.2023HereditasFree full text
  6. Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis.2023Journal of translational medicineFree full text
  7. Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role.2023Lipids in health and diseaseFree full text
  8. S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function.2023Pulmonary pharmacology & therapeutics
  9. The Combined Model of CX3CR1-Related Immune Infiltration Genes to Evaluate the Prognosis of Idiopathic Pulmonary Fibrosis.2022Frontiers in immunologyFree full text
  10. Retrospective analysis of skin photosensitivity induced by pirfenidone.2022Journal of clinical pharmacy and therapeutics
  11. The networks of m6A-SARS-CoV-2 related genes and immune infiltration patterns in idiopathic pulmonary fibrosis.2021AgingFree full text
  12. Investigation of a Hypoxia-Immune-Related Microenvironment Gene Signature and Prediction Model for Idiopathic Pulmonary Fibrosis.2021Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07909655Study sitePhase 2Start 2026-11
  2. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  3. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  4. Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy AdultsCompletedNCT03619616Study sitePhase 1Start 2018-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

4 hospitals in Changsha for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical characteristics and GAA gene mutation in children with glycogen storage disease type II: an analysis of 3 cases].2017Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Changsha for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Changsha for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 0020242025: 002025

7 hospitals in Changsha for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyGastroenterology / hepatologyClinical trials / research unit
Papers it led4
  1. Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study.2023European journal of medical researchFree full text
  2. Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model.2023Frontiers in endocrinologyFree full text
  3. Iron metabolism and chronic inflammation in IgA nephropathy.2023Renal failureFree full text
  4. A Mendelian randomization study to assess the genetic liability of type 1 diabetes mellitus for IgA nephropathy.2022Frontiers in endocrinologyFree full text
Earlier papers (2016–2020)2
  1. CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?2017Current gene therapy
  2. Identification of a novel collagen type IV alpha-4 (COL4A4) mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing.2016The Indian journal of medical research
All its trials on ClinicalTrials.gov, any status5
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  4. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  5. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Changsha for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. COL1A2 p.Gly1066Val variant identified in a Han Chinese family with osteogenesis imperfecta type I.2019Molecular genetics & genomic medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led no English-language PubMed papers on Leber hereditary optic neuropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changsha for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Identification of an ND4 Mutation in Leber Hereditary Optic Neuropathy.2017Optometry and vision science : official publication of the American Academy of Optometry

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中南大学湘雅三医院

Third Xiangya Hospital

长沙

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Third Xiangya Hospital of Central South University; Central South University Third Xiangya Hospital; Transplantation Center of the Third Xiangya Hospital; Third XiangYa Hospital; 中南大学湘雅三医院-门急诊楼

Suggest a correctionDownload the data